DocGo, Inc. Hits New 52-Week Low at $1.02 Amid Financial Struggles

DocGo, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.02 on November 3, 2025. This significant decline reflects a challenging year for the company, which has seen its stock price plummet by 67.81% over the past year, contrasting sharply with the S&P 500's performance of 19.89% during the same period.
The company's financial metrics indicate a difficult operating environment, with a notable drop in operating profit of 478.14% reported in June. DocGo has faced negative results for two consecutive quarters, further highlighting its struggles. The company's return on equity stands at -9.71%, and its price-to-book ratio is at 0.52, suggesting that the stock is trading below its book value.

Additionally, promoter confidence appears to be waning, as stakeholders have reduced their holdings by 2.1% in the last quarter, now owning 4.95% of the company. With net sales reported at a low of USD 80.42 million, DocGo's performance continues to raise concerns among market observers.